Search results
Stopping the march: Can effective treatment of psoriasis prevent progression to psoriatic arthritis?
Medical Xpress· 5 days agoPsoriatic arthritis (PsA) is a chronic inflammatory arthritis which appears in around one-third of...
Izokibep Marches on for Psoriatic Arthritis
MedPage Today· 1 day agoAfter 16 weeks of treatment in the randomized, placebo-controlled study, 40% and 43% of patients receiving 160 mg of izokibep weekly or biweekly,...
Infusions for psoriatic arthritis: Purpose, medications, benefits
Medical News Today· 4 days agoInfusion therapy for psoriatic arthritis (PsA) involves administering medications known as biologics...
The Best Products For Treating Psoriasis, According To Dermatologists
HuffPost· 5 days ago“[It] commonly arises on the scalp, ears, elbows, knees and nails,” she said. “In addition to the...
Izokibep shows promise in psoriatic arthritis trial By Investing.com
Investing.com· 2 weeks agoACELYRIN, INC. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology, announced...
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular...
Morningstar· 2 weeks ago"RINVOQ has been an important addition to the treatment landscape for various rheumatic diseases, helping adult patients achieve meaningful disease control," said Roopal Thakkar, M.D., senior ...
What's in a Name: Defining Difficult-to-Treat axSpA and PsA
Medscape· 3 days agoDespite an expanding arsenal of disease-modifying antirheumatic drugs (DMARDs), many patients with...
Congress Asset Management Co. MA Grows Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)
ETF DAILY NEWS· 4 hours agoCongress Asset Management Co. MA grew its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 37.2% during the fourth quarter, according to the company in its most ...
Northwest Wealth Management LLC Makes New $242,000 Investment in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 5 days agoThe institutional investor bought 840 shares of the medical research company’s stock, valued at approximately $242,000. Several other institutional investors have also made changes to their positions in the stock.
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of...
Morningstar· 2 weeks agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders ...